Phase I studies play a critical role in the development of new cancer therapies. These trials are the initial interface between basic and clinical research for "first in human" studies. Successful therapeutic research embodies an iterative process between the clinic and the laboratory during this critical period of initial development. Whereas in the past, phase I trials focused strictly upon defining the toxicity and pharmacokinetics of new agents, the current emphasis requires that more information is efficiently procured without compromising the analysis of safe and effective administration. This mandate requires real-time procurement of pharmacokinetics, pharmacodynamics, and pharmacogenomics as well as meticulous clinical assessment. In this application, both clinical and basic science investigators of The Ohio State University Comprehensive Cancer Center (OSUCCC) join in a collaborative approach to conduct phase I trials of new cancer therapeutic agents and regimens. Investigators will cooperate closely with the National Cancer Institute in developing correlative studies to evaluate clinical outcomes in the context of basic science observations. The present application builds upon approximately 30 years of experience and the scientific strength of the OSUCCC in conducting clinical trials with pertinent biologic measurements. Trials will target agents and strategies with which our faculty has prior preclinical experience and/or cellular and molecular networks under study in their laboratories. The Experimental Therapeutics Program at OSUCCC has expertise in signal transduction pathways, angiogenesis, cell cycle control, selective induction of tumor cell apoptosis, monoclonal antibodies, molecular genetics, histone protein modification, DMA methylation and other basic targeted therapeutic strategies. The Ohio State University represents one of the most comprehensive biomedical research campuses in the world dedicated to interdisciplinary research. Respective scientists associated with experimental therapy of cancer form a critical mass within the Colleges of Medicine and Public Health, Pharmacy, Biological Sciences, Mathematical and Physical Sciences, Veterinary Medicine, Engineering, Dentistry, and Nursing. This is a Phase I clinical trials program designed to achieve the ultimate goals of expedient (yet thorough) dose-finding trials in man with the intention of providing safe and effective new therapy to benefit patients with malignant diseases.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-K (O1))
Program Officer
Ivy, S Percy
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Markowitz, Joseph; Luedke, Eric A; Grignol, Valerie P et al. (2014) A phase I trial of bortezomib and interferon-*-2b in metastatic melanoma. J Immunother 37:55-62
Jones, Jeffrey A; Rupert, Amy S; Poi, Ming et al. (2014) Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. Am J Hematol 89:19-24
Sborov, Douglas W; Nuovo, Gerard J; Stiff, Andrew et al. (2014) A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res 20:5946-55
Hofmeister, Craig C; Poi, Ming; Bowers, Mindy A et al. (2014) A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol 73:249-57
Klisovic, Rebecca B; Blum, William; Liu, Zhongfa et al. (2014) Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 55:1332-6
Wang, Hongyan; Chen, Ping; Wang, Jiang et al. (2013) In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. AAPS J 15:242-9
Ji, Jia; Mould, Diane R; Blum, Kristie A et al. (2013) A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res 19:1269-80
Martin, Ludmila K; Bekaii-Saab, Tanios; Serna, Derek et al. (2013) A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. Onkologie 36:657-60
Chu, B F; Karpenko, M J; Liu, Z et al. (2013) Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol 71:115-21
Nicholas, Courtney; Yang, Jennifer; Peters, Sara B et al. (2013) PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.). PLoS One 8:e74710

Showing the most recent 10 out of 70 publications